Letter Q. Filing? No filing? Filing? No filing. Valeant Pharmaceuticals (VRX) disclosed that due to the resources spent on filing and restatements, the 10-Q will be delayed: As a result of the concentration of resources on completing our restated financial statements included in the Form 10-K, as well as delays in completing our financial reporting for the quarter ended March 31, 2016, we are not able to file, without unreasonable effort or expense, our Form 10-Q for the quarter ended March 31, 2016 (the "Form 10-Q") within the prescribed time period. Valeant does not expect that it will be in a position to file the Form 10-Q within the 5-day extension period provided in Rule 12b-25(b). The Company is working diligently and intends to file the Form 10-Q as promptly as reasonably practicable. Source: SEC Separately, U.S. Attorney's Office is probing contracts between drugmakers, PBMs. That is why Endo International (ENDP) is down. JNJ and MRK are being probed too.